Verona Pharma plc
VRNA
$63.32
-$2.94-4.44%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 51.76% | 21.26% | 39.35% | -174.62% | -82.52% |
| Total Depreciation and Amortization | 13.90% | -2.63% | -1.48% | 2.66% | 26.44% |
| Total Amortization of Deferred Charges | 24.10% | -32.18% | -- | -- | 530.77% |
| Total Other Non-Cash Items | 104.75% | 292.41% | -124.32% | 792.86% | 34.92% |
| Change in Net Operating Assets | -137.02% | -37.50% | -185.28% | 74.45% | 5,764.52% |
| Cash from Operations | 59.91% | 53.98% | -266.36% | -25.66% | -30.84% |
| Capital Expenditure | 0.00% | -- | 100.00% | -81.25% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 0.00% | -- | 100.00% | -81.25% | -- |
| Total Debt Issued | -- | -- | -100.00% | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | -- | -- |
| Issuance of Common Stock | -94.75% | 2,583.21% | -- | -100.00% | -- |
| Repurchase of Common Stock | -2,579.05% | 30.60% | -317.04% | 58.80% | 23.74% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -104.70% | 27,039.84% | -2,933.33% |
| Cash from Financing | -85.71% | 1,428.59% | -104.25% | 5,442.04% | -113.01% |
| Foreign Exchange rate Adjustments | 127.78% | -190.36% | 7,293.75% | 111.35% | -117.71% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -97.40% | 192.94% | -145.79% | 986.42% | -217.24% |